期刊
INTERNATIONAL JOURNAL OF CANCER
卷 136, 期 2, 页码 425-434出版社
WILEY-BLACKWELL
DOI: 10.1002/ijc.29005
关键词
serological biomarkers; Helicobacter pylori; pepsinogens; gastric precancerous lesions; progression
类别
资金
- National Basic Research Development Program of China [2010CB529304]
- Financial Department of Liaoning Province [2008-621]
- Science and Technology Project of Liaoning province [2011225002]
Effectively managing precancerous lesions is crucial to reducing the gastric cancer (GC) burden. We evaluated associations of temporal changes in multiple serological markers (pepsinogen I [PGI], PGII, PGI/II ratio, gastrin-17 and anti-Helicobacter pylori IgG) with risk for progression of gastric precancerous lesions. From 1997 to 2011, repeated esophagogastroduodenoscopies with gastric mucosal biopsies and blood sample collections were conducted on 2,039 participants (5,070 person-visits) in the Zhuanghe Gastric Diseases Screening Program, Liaoning, China. Serum biomarkers were measured using ELISA, and gastric biopsies were evaluated using standardized histologic criteria. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using generalized estimating equations for correlated binary outcomes. The ORs for progression of gastric conditions comparing those whose serum PGI, PGII, and anti-H. pylori IgG levels increased 50% relative to those whose decreased 50% were, respectively 1.67 (CI, 1.22-2.28), 1.80 (CI, 1.40-2.33) and 1.93 (CI, 1.48-2.52). The OR for those whose PGI/II ratio decreased 50% relative to those whose increased 50% was 1.40 (CI, 1.08-1.81), and for those whose PGII and anti-H. pylori IgG levels both increased 50% relative to those whose levels both decreased 50% the OR was 3.18 (CI, 2.05-4.93). Changes in gastrin-17 were not statistically significantly associated with progression. These findings suggest that temporal changes in serum PGI, PGII, PGI/II ratio, and anti-H. pylori IgG levels (especially PGII and anti-H. pylori IgG combined) may be useful for assessing and managing risk for progression of gastric precancerous lesions. What's new? Effectively managing precancerous gastric lesions could reduce the incidence and mortality of gastric cancer (GC). However, only a small percentage of these lesions actually develop into GC. Specific biomarkers would thus be extremely helpful for risk stratification. In this study, the authors evaluated multiple serological markers for any association between temporal changes in these markers and risk of progression to GC. The results indicate that increased serum levels of pepsinogen II and anti-H. pylori IgG may prove useful for predicting an increased risk of progression to GC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据